MAPT and Alzheimer disease: The finding is also consistent with previous studies that have demonstrated Aβ proteins plateau earlier in the AD spectrum, whereas p‐tau levels continue to increase in the prodromal stages of the disease making Aβ less useful for predicting cognitive changes.35